Legal status by country
Is Cardiac glycosides legal?
Written by Aaron CuhaReviewed Sep 2026
How Cardiac glycosides is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Approved | Approved | Approved | Approved |
| Classification | FDA-approved, prescription only | Licensed, prescription only (MHRA) | TGA-registered, prescription only | Health Canada approved, prescription only |
| Note | Digoxin is approved for heart failure and atrial fibrillation. No senolytic indication is approved. Ouabain is not a marketed United States medicine. | Digoxin only, for cardiac indications. | Digoxin only, for cardiac indications. | Digoxin only, for cardiac indications. |
US FDA status: Digoxin is an FDA-approved prescription drug for heart failure and atrial fibrillation; openFDA lists current prescription products plus several discontinued ones. No cardiac glycoside is approved anywhere for a senolytic or ageing indication. Ouabain is not marketed as a medicine in the United States.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.